These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11745762)

  • 21. [Stability testing of meloxicam-containing microcomposites for inhalation].
    Pomázi A; Ambrus R; Szabóné Révész P
    Acta Pharm Hung; 2014; 84(2):55-62. PubMed ID: 25167700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery.
    Pilcer G; Vanderbist F; Amighi K
    Int J Pharm; 2009 Jan; 365(1-2):162-9. PubMed ID: 18782609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel dry powder inhalation system based on dispersion of lyophilisates.
    Claus S; Schoenbrodt T; Weiler C; Friess W
    Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of L-leucine in reducing the moisture-induced deterioration of spray-dried salbutamol sulfate power for inhalation.
    Li L; Leung SSY; Gengenbach T; Yu J; Gao GF; Tang P; Zhou QT; Chan HK
    Int J Pharm; 2017 Sep; 530(1-2):30-39. PubMed ID: 28709940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: development, in vitro characterization and antioxidant activity.
    Ourique AF; Chaves Pdos S; Souto GD; Pohlmann AR; Guterres SS; Beck RC
    Eur J Pharm Sci; 2014 Dec; 65():174-82. PubMed ID: 25263567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.
    Sethuraman VV; Hickey AJ
    AAPS PharmSciTech; 2002; 3(4):E28. PubMed ID: 12916922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers.
    Glover W; Chan HK; Eberl S; Daviskas E; Verschuer J
    Int J Pharm; 2008 Feb; 349(1-2):314-22. PubMed ID: 17904774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
    Karimi K; Katona G; Csóka I; Ambrus R
    J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy.
    Li HY; Seville PC; Williamson IJ; Birchall JC
    J Gene Med; 2005 Mar; 7(3):343-53. PubMed ID: 15515142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
    Lohrmann M; Kappl M; Butt HJ; Urbanetz NA; Lippold BC
    Eur J Pharm Biopharm; 2007 Sep; 67(2):579-86. PubMed ID: 17418548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of directly compressible powders via co-spray drying.
    Gonnissen Y; Remon JP; Vervaet C
    Eur J Pharm Biopharm; 2007 Aug; 67(1):220-6. PubMed ID: 17317123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.
    Jones MD; Buckton G
    Int J Pharm; 2016 Jul; 509(1-2):419-430. PubMed ID: 27265314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low powder mass filling of dry powder inhalation formulations.
    Eskandar F; Lejeune M; Edge S
    Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of powder polydispersity on aerosol generation.
    Chew NY; Chan HK
    J Pharm Pharm Sci; 2002; 5(2):162-8. PubMed ID: 12207868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
    Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
    Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of formulation and operating variables on zanamivir dry powder inhalation characteristics and aerosolization performance.
    Yang Y; Yang Z; Ren Y; Mei X
    Drug Deliv; 2014 Sep; 21(6):480-6. PubMed ID: 24491208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
    Eedara BB; Tucker IG; Das SC
    Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.